Ajay Madan - Feb 28, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Development Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Stock symbol: CRNX
Transactions as of: Feb 28, 2022
Transactions value $: $178,920
Form type: 4
Date filed: 3/2/2022, 08:00 PM
Previous filing: Feb 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Award	$0	+14K	+8.11%	$0.00	186K	Feb 28, 2022	Direct	F1
transaction	CRNX	Common Stock	Sale	$179K	+9K	+5.36%	$19.88	177K	Mar 1, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Common Stock (right to buy)	Award	$0	+65.4K		$0.00	65.4K	Feb 28, 2022	Common Stock	65.4K	$20.02	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.
F2	The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F3	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.